Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222385 | 0.84 | SCN9A (0.34) | EPHX1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3815549 | 0.79 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL23778445 | 0.76 | GAA (0.40) | — | |
| SCHEMBL21801914 | 0.73 | NR1H2 (0.47) | EPHX1 | |
| SCHEMBL21990270 | 0.73 | NR1H2 (0.47) | EPHX1 | |
| Hydrochloric Acid SCHEMBL25343332 | 0.72 | NR1H2 (0.46) | EPHX1 | |
| SCHEMBL12065376 | 0.71 | SCN9A (0.37) | EPHX1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22248806 | 0.71 | CHRNA4 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL4634900 | 0.71 | EPHX1 (0.41) | EPHX1EPHX2KDM1A | |
| SCHEMBL4634897 | 0.71 | EPHX1 (0.41) | EPHX1EPHX2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | EPHX1 1373/4885EPHX2 1633/4885KDM1A 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.